证券代码：688131 证券简称：皓元医药 公告编号：2025-113 转债代码：118051 转债简称：皓元转债 上海皓元医药股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 累计转股情况：上海皓元医药股份有限公司（以下简称"公司"）向不特定对象发行可转换公司债 券"皓元转债"自2025年6月4日开始转股。截至2025年9月30日，累计已有人民币464,000元"皓元转债"转 换为公司股票，累计转股数量为11,412股，占"皓元转债"转股前公司已发行股份总额的0.0054%。 ● 未转股可转债情况：截至2025年9月30日，"皓元转债"尚未转股的金额为821,886,000元，占"皓元转 债"发行总量的99.94%。 ● 本季度转股情况：自2025年7月1日至2025年9月30日期间，"皓元转债"共有人民币414,000元转换为公 司股票，转股数量为10,190股，占"皓元转债"转股前公司已发行股份总额的0.0048%。 一、可转债发行上市概况 经中国证券监督 ...

Market Overview - On October 9, the medical services sector rose by 0.91%, with Jiuzhou Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3933.97, up 1.32%, while the Shenzhen Component Index closed at 13725.56, up 1.47% [1] Top Gainers in Medical Services - Jiuzhou Pharmaceutical (603456) closed at 20.61, up 5.96% with a trading volume of 418,800 shares and a transaction value of 844 million [1] - Meinian Health (002044) closed at 5.20, up 4.63% with a trading volume of 1,667,200 shares and a transaction value of 871 million [1] - Heyuan Biotechnology (688238) closed at 8.20, up 4.19% with a trading volume of 344,500 shares and a transaction value of 285 million [1] - Sanbo Brain Science (301293) closed at 60.80, up 4.02% with a trading volume of 110,100 shares and a transaction value of 660 million [1] - Haoyuan Pharmaceutical (688131) closed at 85.48, up 3.49% with a trading volume of 59,800 shares and a transaction value of 508 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 14.21, down 8.73% with a trading volume of 68,800 shares and a transaction value of 96.92 million [2] - ST Biological (000504) closed at 9.07, down 4.02% with a trading volume of 46,100 shares and a transaction value of 42.42 million [2] - Baicheng Pharmaceutical (301096) closed at 57.99, down 3.35% with a trading volume of 32,600 shares and a transaction value of 191 million [2] Fund Flow Analysis - The medical services sector experienced a net outflow of 308 million from institutional investors, while retail investors saw a net inflow of 348 million [2] - The net outflow from retail investors amounted to 40.85 million [2] Individual Stock Fund Flow - Aier Eye Hospital (300015) had a net inflow of 283 million from institutional investors, while retail investors experienced a net outflow of 137 million [3] - Sanbo Brain Science (301293) saw a net inflow of 63.69 million from institutional investors, with retail investors facing a net outflow of 45.84 million [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 53.54 million from institutional investors, while retail investors faced a net outflow of 63.40 million [3]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-113 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 可转债转股结果暨股份变动公告 未转股可转债情况：截至 2025 年 9 月 30 日，"皓元转债"尚未转股的 金额为 821,886,000 元，占"皓元转债"发行总量的 99.94%。 本季度转股情况：自 2025 年 7 月 1 日至 2025 年 9 月 30 日期间，"皓元 转债"共有人民币 414,000 元转换为公司股票，转股数量为 10,190 股，占"皓 元转债"转股前公司已发行股份总额的 0.0048%。 一、可转债发行上市概况 经中国证券监督管理委员会《关于同意上海皓元医药股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可[2024]1289 号）同意，上海 皓元医药股份有限公司（以下简称"公司"、"本公司"）于 2024 年 11 月 28 日 向不特定对象发行 822.35 万张可转换公司债券，每张面值为人民币 100 元，发 行总额 82,235.00 万元 ...

Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]

Group 1 - The core viewpoint of the news is that Haoyuan Pharmaceutical has seen a stock price increase of 5.07% as of September 30, reaching 81.60 CNY per share, with a total market capitalization of 17.307 billion CNY [1] - Haoyuan Pharmaceutical, established on September 30, 2006, specializes in the research and development of molecular building blocks and tool compounds in the small molecule drug discovery field, as well as the process development and production technology improvement of active pharmaceutical ingredients (APIs) and intermediates [1] - The company's main business revenue composition includes molecular building blocks, tool compounds, and biochemical reagents at 68.97%, with product sales contributing 63.42%, APIs and intermediates at 30.46%, technical services at 5.55%, and other sources at 0.57% [1] Group 2 - From the perspective of fund holdings, Haoyuan Pharmaceutical is a top ten holding of the Hengsheng Qianhai Fund, specifically in the Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332), which held 24,600 shares, accounting for 2.1% of the fund's net value [2] - The fund has achieved a year-to-date return of 39.78%, ranking 2105 out of 8167 in its category, and a one-year return of 45.37%, ranking 2370 out of 8010 [2] Group 3 - The fund manager of Hengsheng Qianhai Hong Kong-Shenzhen Emerging Industry Selected Mixed Fund (004332) is Xing Cheng, who has been in the position for 3 years and 193 days, with the fund's total asset size at 252 million CNY [3] - During Xing Cheng's tenure, the best fund return was 87.69%, while the worst return was -29.15% [3]

Core Viewpoint - The company announces the suspension of the conversion of its convertible bonds "Hao Yuan Convertible Bonds" during the implementation of the 2025 semi-annual profit distribution plan, which includes a cash dividend of 0.80 yuan per 10 shares [2][3]. Summary by Sections 1. Securities Suspension and Resumption - The "Hao Yuan Convertible Bonds" will stop conversion from October 13, 2025, until the equity registration date for the profit distribution [2][4]. - The bonds will resume conversion on the first trading day after the equity registration date [4]. 2. Profit Distribution Plan - The company will distribute a cash dividend of 0.80 yuan (including tax) for every 10 shares based on the total share capital registered on the equity registration date [3]. - The distribution plan does not include bonus shares or capital reserve conversion into share capital [3]. - The company will adjust the conversion price of the "Hao Yuan Convertible Bonds" according to the terms outlined in the prospectus after the profit distribution [3]. 3. Additional Information - Detailed information regarding the "Hao Yuan Convertible Bonds" can be found in the prospectus disclosed on November 26, 2024 [5].

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-112 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 上海皓元医药股份有限公司 关于实施 2025 年半年度权益分派时"皓元转债" 停止转股的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券停复牌情况：适用 因实施 2025 年半年度权益分派，上海皓元医药股份有限公司（以下简称"公 司"）的相关证券停复牌情况如下：权益分派实施公告披露日前一交易日（2025 年 10 月 13 日）至权益分派股权登记日期间，公司可转换公司债券"皓元转债"将停 止转股。 具 体 内 容 详 见 公 司 于 2025 年 8 月 29 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《上海皓元医药股份有限公司关于 2025 年半年度利润 分配方案的公告》（公告编号：2025-100）。 本次权益分配方案实施后，公司将根据《上海皓元医药向不特定对象发行可 ...

Core Viewpoint - The company has announced adjustments to the grant prices of its restricted stock incentive plans for 2023 and 2025, reflecting changes due to upcoming dividend distributions and compliance with relevant regulations [11][29]. Group 1: Board Meeting and Resolutions - The fourth board meeting was held on September 26, 2025, with all seven directors present, confirming the legality and validity of the meeting [1][2]. - The board approved the adjustment of the grant price for the 2023 restricted stock incentive plan from 22.56 CNY/share to 22.48 CNY/share [11][27]. - The board also approved the adjustment of the grant price for the 2025 restricted stock incentive plan from 21.62 CNY/share to 21.39 CNY/share [5][28]. Group 2: Adjustment Reasons and Methods - The adjustments were made in light of the company's 2024 annual dividend distribution and the upcoming 2025 semi-annual dividend distribution [25][26]. - The adjustment method for the 2023 plan involved reducing the grant price by the amount of cash dividends distributed, resulting in a new price of 22.48 CNY/share [27]. - Similarly, the adjustment for the 2025 plan was calculated using the same method, leading to a new grant price of 21.39 CNY/share [28]. Group 3: Compliance and Legal Opinions - The adjustments have been reviewed and approved by the board's remuneration and assessment committee, ensuring compliance with relevant laws and regulations [30][31]. - Legal opinions from Shanghai Guangfa Law Firm and DeHeng Law Firm confirmed the legality and validity of the adjustments for both incentive plans [32][34].

上海皓元医药股份有限公司 关于调整 2023 年、2025 年限制性股票激励计划 授予价格的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 2023 年限制性股票激励计划的第二类限制性股票授予价格由 22.56 元/ 股调整为 22.48 元/股； 2025 年限制性股票激励计划的授予价格由 21.62 元/股调整为 21.39 元/ 股。 上海皓元医药股份有限公司（以下简称"公司"）于 2025 年 9 月 26 日召 开的第四届董事会薪酬与考核委员会第五次会议、第四届董事会第十二次会议 审议通过了《关于调整 2023 年、2025 年限制性股票激励计划授予价格的议案》， 同意根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《上 海证券交易所科创板股票上市规则》（以下简称"《上市规则》"）、2023 年 限制性股票激励计划（草案）》（以下简称"《2023 年激励计划（草案）》"）、 《2025 年限制性股票激励计划（草案）》（以下简称"《2025 年激励计划（草 案）》"）的有关规定，以 ...

2023 2 3 4 5 根据 2024 年年度股东大会的授权,公司于 2025 年 8 月 26 日召开第四届董 事会审计委员会第五次会议、于 2025 年 8 月 27 日召开第四届董事会第十一次会 议,审议通过了《关于 2025年半年度利润分配方案的议案》,公司拟以权益分派 股权登记日的总股本为基数,向全体股东每股派发现金红利 0.08元（含税）。根 据《管理办法》《股票激励计划》等相关规定，需对本次股权激励计划的授予价 格进行相应调整。 6 股。 2、2025年 9 月 26 日,公司召开第四届董事会薪酬与考核委员会第五次会 议，董事会薪酬与考核委员会认为:鉴于公司拟实施 2025 年半年度权益分派, 根据《2023 年激励计划(草案)》的相关规定及公司 2023 年第二次临时股东大 会的授权,对 2023年激励计划的授予价格进行调整,审议程序合法合规,符合 《管理办法》等有关法律、法规、规范性文件的相关规定,不存在损害公司及全 体股东利益的情形 本所认为,公司本次股权激励计划授予价格调整事项已获得必要的批准和授 权，符合《管理办法》及《股票激励计划》的有关规定。 二、关于本次股权激励计划授予价格的调 ...